Case report: Mucormycosis due to Rhizopus microsporus: an important reminder of opportunistic infections in immunocompromised acute myeloid leukemia

被引:1
作者
Higuchi, Misato [1 ]
Nishimoto, Katsutaro [2 ]
Waseda, Tomoka [1 ]
Takenaka, Motoi [1 ,3 ]
Murota, Hiroyuki [1 ,3 ]
机构
[1] Nagasaki Univ Hosp, Dept Dermatol & Allergol, Nagasaki, Japan
[2] Nagasaki Ekisaikai Hosp, Dept Dermatol, Nagasaki, Japan
[3] Nagasaki Univ, Dept Dermatol, Grad Sch Biomed Sci, Nagasaki, Japan
关键词
immnocompromised; mucormycosis; Rhizopus microspores; acute myeloid leukemia; infection;
D O I
10.3389/jcia.2024.13995
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hematologic malignancies, diabetes, and the development and widespread use of novel anticancer and immunosuppressive agents have introduced a new dimension of immunosuppression, raising concerns about emerging opportunistic infections. Here, we report a case of mucormycosis in a patient with therapy-related acute myeloid leukemia, encountered in our department. The patient presented with a necrotic lesion around the right eyelid. In this case, the condition and skin lesions rapidly progressed, and the patient passed away within a few days of the appearance of necrotic plaques. The causative organism was identified as Rhizopus microsporus. Mucormycosis is a severe invasive fungal infection that can rapidly worsen the prognosis of immunocompromised patients. Cutaneous mucormycosis is classified into primary and secondary forms. Based on the findings and the underlying disease, secondary cutaneous mucormycosis was suspected. Familiarity with the characteristic clinical features of mucormycosis may be the key factor in initiating timely treatment.
引用
收藏
页数:4
相关论文
共 9 条
[1]   MUCORMYCOSIS IN THE IMMUNOCOMPROMISED HOST [J].
BHADURI, S ;
KURRLE, E ;
VANEK, E ;
SPANEL, R .
INFECTION, 1983, 11 (03) :170-172
[2]   Cutaneous zygomycosis [J].
Bonifaz, Alexandro ;
Vazquez-Gonzalez, Denisse ;
Tirado-Sanchez, Andres ;
Maria Ponce-Olivera, Rosa .
CLINICS IN DERMATOLOGY, 2012, 30 (04) :413-419
[3]   Cutaneous mucormycosis [J].
Castrejon-Perez, Ana Daniela ;
Miranda, Ivett ;
Welsh, Oliverio ;
Welsh, Esperanza C. ;
Ocampo-Candiani, Jorge .
ANAIS BRASILEIROS DE DERMATOLOGIA, 2017, 92 (03) :304-309
[4]   THE IMMUNOCOMPROMISED HOST [J].
GORENSEK, MJ .
DERMATOLOGIC CLINICS, 1989, 7 (02) :353-367
[5]  
Kakeya H, 2024, MED MYCOL J, V65, P29, DOI 10.3314/mmj.24.002
[6]  
Kanda Y., 2023, Med Mycol J, V64, P77, DOI [10.11534/ishinkin.23.005, DOI 10.11534/ISHINKIN.23.005]
[7]   Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review [J].
Liang, Mei ;
Xu, Jian ;
Luo, Yanan ;
Qu, Junyan .
ANNALS OF MEDICINE, 2024, 56 (01)
[8]  
Reich HL, 2004, J AM ACAD DERMATOL, V50, pS114
[9]   Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis [J].
Scheckenbach, Kathrin ;
Cornely, Oliver ;
Hoffmann, Thomas K. ;
Engers, Rainer ;
Bier, Henning ;
Chaker, Adam ;
Greve, Jens ;
Schipper, Joerg ;
Wagenmann, Martin .
AURIS NASUS LARYNX, 2010, 37 (03) :322-328